Galderma Group AG has announced its sales performance for the first nine months of 2024, reporting record net sales, of $3.259 billion, a growth of 9.2 % compared to last year.
Flemming Ørnskov, M.D., MPH, CEO of Galderma stated,
“By executing on our unique Integrated Dermatology Strategy, Galderma continues its strong growth trajectory, driven by momentum behind our science-based premium brands. The exciting progress with our late-stage pipeline with key regulatory approvals and differentiated innovations positions Galderma for continued strong growth. Combined with our high-performing commercial execution and increasing penetration in existing and new key markets, this sets the stage for further growth acceleration and value creation.”
Net sales growth was widespread across product categories and geographies. All product categories grew, with notable sustained double-digit growth in Injectable Aesthetics and Dermatological Skincare.
Continued performance across all product categories with constant currency year-on-year growth of 10.6% for Injectable Aesthetics, 10.6% for Dermatological Skincare, and 2.9% for Therapeutic Dermatology for the first nine months of 2024.
Net sales in Injectables Aesthetics reached $1,698 million. Dermatological Skincare’s net sales were $990 million, with growth driven by its Cetaphil and Alastin brands. Therapeutic Dermatology net sales reached $571 million.
Galderma expects full-year net sales growth to be in the range of 8.8-9.5% year-on-year at constant currency. It was previously expected towards the upper end of the 7-10% growth range at constant currency.
Flemming Ørnskov, M.D., MPH, CEO of Galderma stated,
“By executing on our unique Integrated Dermatology Strategy, Galderma continues its strong growth trajectory, driven by momentum behind our science-based premium brands. The exciting progress with our late-stage pipeline with key regulatory approvals and differentiated innovations positions Galderma for continued strong growth. Combined with our high-performing commercial execution and increasing penetration in existing and new key markets, this sets the stage for further growth acceleration and value creation.”
Net sales growth was widespread across product categories and geographies. All product categories grew, with notable sustained double-digit growth in Injectable Aesthetics and Dermatological Skincare.
Continued performance across all product categories with constant currency year-on-year growth of 10.6% for Injectable Aesthetics, 10.6% for Dermatological Skincare, and 2.9% for Therapeutic Dermatology for the first nine months of 2024.
Net sales in Injectables Aesthetics reached $1,698 million. Dermatological Skincare’s net sales were $990 million, with growth driven by its Cetaphil and Alastin brands. Therapeutic Dermatology net sales reached $571 million.
Galderma expects full-year net sales growth to be in the range of 8.8-9.5% year-on-year at constant currency. It was previously expected towards the upper end of the 7-10% growth range at constant currency.
Read Next
L’Oréal Acquires 10% Stake in Galderma
Galderma Reports Net Sales of Over $1 Billion in Q1 and 12.4% Year-on-Year Growth
